Compare CLNE & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNE | ENTA |
|---|---|---|
| Founded | 2001 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.1M | 378.0M |
| IPO Year | 2006 | 2012 |
| Metric | CLNE | ENTA |
|---|---|---|
| Price | $1.63 | $13.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $3.32 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 2.0M | 195.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $341,599,000.00 | $102,814,000.00 |
| Revenue This Year | $1.13 | $7.76 |
| Revenue Next Year | $22.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $1.54 | $7.05 |
| 52 Week High | $3.11 | $17.15 |
| Indicator | CLNE | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 37.74 | 50.26 |
| Support Level | $1.55 | $13.47 |
| Resistance Level | $2.40 | $13.98 |
| Average True Range (ATR) | 0.07 | 0.67 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 19.35 | 36.99 |
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.